Services on Demand
Revista do Instituto de Medicina Tropical de São Paulo
On-line version ISSN 1678-9946
SILVA-VERGARA, Mario León et al. Azithromycin in the treatment of mucosal leishmaniasis. Rev. Inst. Med. trop. S. Paulo [online]. 2004, vol.46, n.3, pp. 175-177. ISSN 1678-9946. http://dx.doi.org/10.1590/S0036-46652004000300011.
This report describes three elderly patients with mucosal form of American tegumentary leishmaniasis associated with chronic cardiopathy. Due to the known toxicity of classical drugs with activity against Leishmania sp., the patients received three oral courses of azithromycin therapy in single 500 mg daily dose during ten days, every other month. All lesions healed after the third series. One of the patients relapsed and a new series of azithromycin was prescribed. Azithromycin may be an alternative drug for the treatment of leishmaniasis in special situations due to its optimal mucosal and intraphagocyte concentration, single daily posology, high tolerance and oral administration. The mechanism of this drug on Leishmania sp. is unknown at present.
Keywords : Mucosal leishmaniasis; Azithromycin; Chronic cardiopathy.